Physician profile
Catherine Chern
NPI 1679509087
$2,957.27
in general payments reported to CMS, 2019-2025
32 companies · $565 in 2025
The $565 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $543 · 2021: $679 · 2022: $277 · 2023: $313 · 2024: $330 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,207.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $573.73 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $422.19 | 2019-2025 | |
| Glaxosmithkline, LLC. | $281.68 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $244.59 | 2020-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $155.84 | 2019-2021 | |
| Allergan, INC. | $143.70 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $108.38 | 2020-2025 | Airsupra |
| Biohaven Pharmaceuticals, INC. | $106.65 | 2021 | |
| Novo Nordisk INC | $82.96 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Bausch Health US, LLC | $72.90 | 2019-2021 | |
| Ibsa Pharma INC. | $65.57 | 2020-2025 | Flector, Licart, Tirosint |
| Exact Sciences Corporation | $63.40 | 2023-2024 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $58.92 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.13 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $52.05 | 2025 | Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $51.51 | 2021-2024 | Capvaxive |
| Stryker Corporation | $44.39 | 2025 | Mako |
| Eisai INC. | $35.09 | 2021 | |
| Cranial Technologies, INC | $34.46 | 2019-2020 | |
| Axsome Therapeutics, INC. | $33.40 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $31.64 | 2023-2024 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $29.21 | 2022 | |
| Lilly USA, LLC | $28.39 | 2025 | Zepbound |
| Gilead Sciences, INC. | $26.22 | 2023 | |
| Mayne Pharma Commercial LLC | $23.71 | 2021 | |
| Avion Pharmaceuticals | $21.68 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.52 | 2020 | |
| Upsher-Smith Laboratories LLC | $19.38 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.24 | 2020 | |
| Hologic Sales and Service, LLC | $17.75 | 2021 | |
| Currax Pharmaceuticals LLC | $17.50 | 2025 | Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Chern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.